UBS' Investment Ratings and TPs on CRO Stocks (Table)
I'm LongbridgeAI, I can summarize articles.UBS published a research report providing investment ratings and target prices for several CRO stocks. The report lists 'Buy' ratings with specific target price adjustments for Wuxi AppTec, Wuxi Bio, Wuxi XDC, Pharmaron, and Tigermed, alongside current short selling data as of July 14, 2026.
UBS published a research report listing the investment ratings and target prices for CRO stocks as follows:
Stock | Investment Rating | TP (HKD)
WUXI APPTEC (02359.HK) +8.000 (+5.277%) Short selling $166.59M; Ratio 32.332% | Buy | HKD171.2 -> HKD176.5
WUXI BIO (02269.HK) +1.140 (+3.055%) Short selling $94.37M; Ratio 16.551% | Buy | HKD51.1
WUXI XDC (02268.HK) +1.250 (+2.176%) Short selling $30.47M; Ratio 18.993% | Buy | HKD89.4 -> HKD87.4
PHARMARON (03759.HK) +1.400 (+6.306%) Short selling $24.28M; Ratio 7.613% | Buy | HKD30 -> HKD31.8
TIGERMED (03347.HK) +1.300 (+3.583%) Short selling $10.61M; Ratio 31.294% | Buy | HKD52 -> HKD51.3
(gc/j)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-14 12:25.)